Eventide Asset Management LLC Has $108.43 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Eventide Asset Management LLC cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 39.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 690,632 shares of the company’s stock after selling 454,798 shares during the quarter. TransMedics Group comprises 1.9% of Eventide Asset Management LLC’s portfolio, making the stock its 10th largest position. Eventide Asset Management LLC owned approximately 2.06% of TransMedics Group worth $108,429,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TMDX. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $55,000. J.Safra Asset Management Corp increased its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC raised its stake in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after acquiring an additional 316 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,958 shares of company stock valued at $3,470,328. Insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 8.1 %

Shares of TransMedics Group stock opened at $87.11 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The business has a fifty day simple moving average of $113.26 and a two-hundred day simple moving average of $136.45. TransMedics Group, Inc. has a 1 year low of $67.77 and a 1 year high of $177.37. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 92.67 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.12) EPS. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. cut their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Piper Sandler lowered their price objective on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. TD Cowen decreased their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Oppenheimer lowered their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.